NCT05167851View on ClinicalTrials.gov

The Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

December 31, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Lazertinib , a combination group of SBRT

"\* Lazertinib 240mg once a day(QD) oral(PO)~-If there is no disease progression or unacceptable toxicity, treatment is performed at 1 cycle (28 days) interval . This is expected to be an average of one year."

DRUG

Lazertinib single administration group

"\* Lazertinib 240mg once a day(QD) oral(PO)~-If there is no disease progression or unacceptable toxicity, treatment is performed at 1 cycle (28 days) interval . This is expected to be an average of one year."

Trial Locations (1)

Unknown

Yonsei University Health System, Severance Hospital, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER